NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $1.62 -0.08 (-4.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.59▼$1.7350-Day Range$1.17▼$2.4652-Week Range$1.14▼$4.02Volume413,436 shsAverage Volume673,869 shsMarket Capitalization$77.95 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioAtla alerts: Email Address BioAtla MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside435.0% Upside$8.67 Price TargetShort InterestHealthy8.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.60) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector365th out of 936 stocksBiological Products, Except Diagnostic Industry54th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioAtla has only been the subject of 2 research reports in the past 90 days.Read more about BioAtla's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.27% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in BioAtla has recently decreased by 24.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 3.8 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioAtla this week, compared to 1 article on an average week.Search Interest4 people have searched for BCAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added BioAtla to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($1.60) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioAtla's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About BioAtla Stock (NASDAQ:BCAB)BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Read More BCAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Stock News HeadlinesJuly 25 at 5:39 PM | globenewswire.comBioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 23 at 4:50 PM | markets.businessinsider.comBioAtla Says Its Drug Ozuriftamab Vedotin To Treat SCCHN Got Fast Track DesignationJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 9, 2024 | 247wallst.com3 Penny Stocks With 735% Average Upside, According to Wall StreetMay 29, 2024 | globenewswire.comBioAtla to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comBioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | markets.businessinsider.comBuy Rating for BioAtla: Promising Clinical Data and Strong Financial Position Signal Upside PotentialMay 23, 2024 | finance.yahoo.comInstitutional owners may consider drastic measures as BioAtla, Inc.'s (NASDAQ:BCAB) recent US$35m drop adds to long-term lossesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline ProgressMay 15, 2024 | msn.comBioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comBioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...May 14, 2024 | investorplace.comBCAB Stock Earnings: BioAtla Beats EPS for Q1 2024May 14, 2024 | globenewswire.comBioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressMay 8, 2024 | globenewswire.comBioAtla to Participate in the Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comBioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024May 6, 2024 | markets.businessinsider.comBioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple TumorsMay 6, 2024 | globenewswire.comBioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple TumorsSee More Headlines Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+428.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-140.44% Return on Assets-88.35% Debt Debt-to-Equity RatioN/A Current Ratio4.49 Quick Ratio4.49 Sales & Book Value Annual Sales$250,000.00 Price / Sales315.64 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.12Miscellaneous Outstanding Shares48,116,000Free Float42,583,000Market Cap$78.91 million OptionableOptionable Beta1.06 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jay M. Short Ph.D. (Age 66)Co-Founder, CEO & Chairman Comp: $1.13MMr. Richard A. Waldron (Age 70)Senior VP & CFO Comp: $655.94kDr. Eric L. Sievers M.D. (Age 60)Chief Medical Officer Comp: $654.59kMr. Christian J. Vasquez (Age 48)Chief Accounting Officer, Controller and Corporate Secretary Comp: $408.75kMs. Susie MelodySenior Vice President of Human ResourcesDr. Cathy Chang Ph.D.Senior Vice President of Research & DevelopmentDr. Gerhard Frey Ph.D.Senior Vice President of Technology DevelopmentMs. Monica SullivanSenior Vice President of Intellectual Property & ContractsMs. Sheri LydickChief Commercial OfficerDr. Bin ZhangSenior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXScilexNASDAQ:SCLXSolid BiosciencesNASDAQ:SLDBPoseida TherapeuticsNASDAQ:PSTXSutro BiopharmaNASDAQ:STROView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 30,012 shares on 5/20/2024Ownership: 0.062%Tidal Investments LLCSold 9,072 shares on 5/17/2024Ownership: 0.302%Price T Rowe Associates Inc. MDBought 12,791 shares on 5/15/2024Ownership: 0.027%Vanguard Group Inc.Bought 17,667 shares on 5/10/2024Ownership: 4.364%Acadian Asset Management LLCBought 56,748 shares on 5/10/2024Ownership: 0.323%View All Insider TransactionsView All Institutional Transactions BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $2.46 at the start of the year. Since then, BCAB shares have decreased by 34.1% and is now trading at $1.62. View the best growth stocks for 2024 here. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
